3rd Quarter - Report
THE MCMANUS GROUP for GILEAD SCIENCES, INC.
Firm
Client
Income
$80,000
Expenses
—
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Budget/Appropriations BUD
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Health Issues HCR
Support for H.R. 2430 - FDA Reauthorization Act of 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.